Gilead's Lenacapavir Expansion Fails to Address Global HIV Access Inequities

Strategic Insights -

As Gilead Sciences expands lenacapavir, a long-acting HIV treatment, to 120 countries through voluntary licensing agreements with six generic manufacturers, the AIDS Healthcare Foundation (AHF) is highlighting the alarming exclusions of key HIV-affected countries in Latin America and others from the deal. According to AHF, this license excludes 2 million people living with HIV in countries like Brazil, Mexico, Argentina, Colombia, and Peru, further exacerbating existing global HIV access inequities. AHF President Michael Weinstein emphasizes that lenacapavir's promise to save countless lives must be made affordable to all nations that need it, not just those where Gilead can profit.

Key Takeaways:

  • The Gilead-lenacapavir licensing agreement excludes 2 million people living with HIV in Latin America, particularly in Brazil, Mexico, Argentina, Colombia, and Peru.
  • AHF strongly believes lenacapavir must be made accessible to all countries at an affordable price, which is crucial for achieving global HIV/AIDS targets.
  • The deal includes six generic manufacturers in India, Pakistan, Egypt, and the US, but excludes South Africa's robust pharmaceutical sector to address its own enormous HIV burden.
  • Gilead and licensees have yet to clarify lenacapavir's pricing in the included countries, raising concerns about pricing transparency.
  • AHF has called for greater affordability and transparency in pricing to ensure the treatment is accessible to all who need it.
  • AHF emphasizes that lenacapavir's development is a significant step forward in improving treatment adherence, but its promise cannot be fulfilled if it is not made accessible to all nations.
  • AHF President Michael Weinstein has stated that Gilead sees the Latin American market as a place where it can profit off the backs of sick people, further highlighting concerns about duplicity.

Statistics:

  • 2 million people living with HIV in Latin America are excluded from the Gilead-lenacapavir deal.
  • 120 countries will have access to lenacapavir through voluntary licensing agreements with six generic manufacturers.
  • Gilead and licensees have yet to clarify lenacapavir's pricing in the included countries.
  • AIDS Healthcare Foundation (AHF) has a global presence in 48 countries, providing cutting-edge medicine and advocacy to over 2 million people in those countries.

Sources:

  • The AIDS Healthcare Foundation (AHF)
  • Michael Weinstein, AHF President